Company Description
Aurion Biotech is a clinical-stage biotechnology company committed to developing and commercializing disease-modifying, regenerative therapies to restore vision to millions of patients worldwide.
We are advancing a single administration, allogeneic cell therapy to treat vision loss due to corneal endothelial diseases.
In Japan, our first-generation cell therapy product, HCEC-1, received regulatory and reimbursement approval, and launched commercially in September 2024 under the marketed name Vyznova.
Our next-generation product candidate, AURN001, is an improved formulation designed to be mechanistically identical to Vyznova and to provide enhanced benefits, including manufacturing scalability and extended shelf life.
AURN001 has been developed leveraging data generated globally across five completed clinical trials in 154 procedures in 130 subjects, including four trials evaluating HCEC-1 and one trial evaluating AURN001.
We have completed enrollment and dosed 97 subjects in a Phase 1/2 clinical trial for AURN001 in the United States and Canada, and 12-month data from this trial is expected in the second half of 2025.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Gregory D. Kunst, M.B.A. |
Contact Details
Address: 701 Pike Street, Suite 2225 Seattle, WA 98101 United States | |
| Phone | 206-210-0058 |
| Website | aurionbiotech.com |
Stock Details
| Ticker Symbol | AURN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001924356 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gregory D. Kunst, M.B.A. | Chief Executive Officer and Director |
| Michael H. Goldstein, M.D., M.B.A. | President and Chief Medical Officer |
| Arnaud Lacoste, M.B.A., Ph.D. | Chief Scientific Officer |
| Jonathan M. Sparks, J.D., Ph.D. | Chief Legal Officer |
| Matthew Fowler, M.B.A. | Vice President of Accounting & Finance Operations |
| Thomas Frinzi | Director and Executive Chair |
| Thomas R. Hudnall, J.D. | Director |
| Andrew ElBardissi, M.D. | Director |
| Patrick Lally, M.B.A. | Director |
| Christine Z. McCauley, M.S.H.R.M. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | RW | Filing |
| Jan 24, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 10, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Oct 21, 2024 | DRS | [Cover] Draft Registration Statement |
| Apr 25, 2022 | D | Notice of Exempt Offering of Securities |
| Apr 21, 2022 | D | Notice of Exempt Offering of Securities |
| Apr 21, 2022 | D | Notice of Exempt Offering of Securities |